[Pretreatment evaluation of CA 72.4 in patients with carcinoma of the stomach (0-IV stage) versus CEA, TPA, CA 19-9, FER].
Before surgical treatments, sera of 54 pts suffering from gastric cancer, histologically typed and clinically staged (from stage 0 to 4), were assayed to evaluate CEA, TPA, CA 19-9 and Ferritin versus a new tumoral marker called TAG-72, in order to determine the biological behaviour and the relation to the clinical stage of this last one. Starting from their results, Authors say that the new marker TAG 72 has an increasing sensibility according to the clinical stage (4 th more than 1 st), and that the association of the TAG-72 plus CEA and/or TPA is rather significant in order to evaluate the evolution of the gastric cancer than other markers.
Buda
F
F
Aragona
P
P
Giani
G
G
Sisto
R
R
Di Nardo
G
G
Binotto
F
F
Gangemi
P
P
De Zerbi
T
T
Gentile
G
G
Papadia
A
A
D000368:Aged; D000951:Antigens, Neoplasm / Q000032:analysis*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D005260:Female; D005293:Ferritins / Q000032:analysis*; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010455:Peptides / Q000032:analysis*; D011300:Preoperative Care; D013274:Stomach Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery; D019396:Tissue Polypeptide Antigen
D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen; D006023:Glycoproteins; D010455:Peptides; D019396:Tissue Polypeptide Antigen; C047052:tumor-associated antigen 72; D005293:Ferritins
Valutazione pretrattamento del CA 72.4 in pazienti con carcinoma gastrico (stadio 0-IV) vs CEA, TPA, CA 19-9 FER.